Items Tagged ‘anticancer drugs’

March 28, 2012

Drug Candidates Derailed in Case of Mistaken Identity

By

Scott Kaufmann fears a rush to judgement. He studies DNA-repair proteins called poly(ADP-ribose) polymerases, or PARPs, that have shown promise as targets for anticancer drugs. Until early last year, compounds that inhibit PARPs were the next big thing in cancer drug development (see ‘Suspect class’). Then, a leading candidate PARP inhibitor called iniparib failed a […]

View full entry

Tags: anticancer drugs, PARPs, Scott Kaufmann


Contact Us · Privacy Policy